



Alzheimer's
Drug Discovery
Foundation



The Association for
Frontotemporal Degeneration
Opening the gateway to help and a cure

REQUEST FOR PROPOSALS

Accelerating DRUG DISCOVERY for Frontotemporal Degeneration

Research investigating the pathologic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative drug discovery programs for FTD through this Request for Proposals (RFP).

Priority areas for this program include:

- Development and testing of novel high throughput screening assays
- Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies.
- Testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept

MECHANISM(S) OF SUPPORT: ADDF/AFTD will provide grants for one-year duration with the possibility of follow-on funding. Budgets averaging \$100,000-\$150,000 are recommended. Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program-related investment.

REVIEW PROCESS: The deadline date for applications is **September 2nd, 2016**. Submission of a Letter of Intent (LOI) is required prior to August 12th, 2016. LOIs are reviewed on a rolling basis and can be submitted any time prior to the date above. Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee, including members of AFTD's Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF's external Business Advisory Board.

APPLICATION PROCEDURE

All letters of intent and applications must be submitted electronically at www.alzdiscovery.org. For additional educational resources and access to Contract Research Organizations (CROs), please visit

ADDF ACCESS: <https://addfaccess.ondeckbiotech.com/>

To further discuss scientific or financial aspects of proposals, please contact:

Diana Shineman, PhD, Director for Scientific Affairs, ADDF

Phone: 212-901-8007 / E-mail: dshineman@alzdiscovery.org

Nadine Tatton, PhD, Scientific Director, AFTD

Phone: 267-514-7221 / Email: ntatton@theaftd.org

For more information regarding the application process, please contact:

Dan Teng, Grants Assistant

Phone: 212-901-7998 / E-mail: dteng@alzdiscovery.org